| 刘 铮,印卫锋,任 晔,郝 萍,王 江.云南肺癌易感性与HLA-A，HLA-B，DRB1，DQB1等位基因频率的相关性研究[J].,2017,17(21):4038-4042 |
| 云南肺癌易感性与HLA-A，HLA-B，DRB1，DQB1等位基因频率的相关性研究 |
| A Correlative Study on Lung Cancer with the Frequency of HLA-A, HLA-B, DRB1, DQB1 Alleles in Yunnan Province |
| 投稿时间：2016-12-10 修订日期：2016-12-30 |
| DOI：10.13241/j.cnki.pmb.2017.21.009 |
| 中文关键词: 云南肺癌 基因频率相关性 人类白细胞抗原 相关性研究 等位基因 |
| 英文关键词: Yunnan lung cancer Gene frequency association Human leukocyte antigens Correlative analysis Alleles |
| 基金项目:国家自然科学基金项目（30260103）；云南省自然科学基金项目（2002C0053M） |
|
| 摘要点击次数: 226 |
| 全文下载次数: 165 |
| 中文摘要: |
| 摘要 目的：测定云南肺癌患者人类白细胞抗原(human leukocyte antigen，HLA)-A、B、DRB1、DQB1等位基因出现频率，探讨HLA各等位基因位点与云南省肺癌发病易感性的相关性。方法：采用病例-对照相关分析方法，选取云南籍肺癌患者和健康个体各30例，应用序列特异性引物聚合酶链反应(polymerase chain reaction-sequence specific primer，PCR-SSP)对HLA-A、HLA-B、HLA-DRB1及HLA-DQB1等位基因频率进行测定，与正常组对比测算相对危险因子(relative risk，RR)。结果：肺癌组的HLA-A*02频率为90.0% (A*0201为主)，B*46频率为40.0%，DRB1*15频率为40.0%，较对照组的43.30%、0%、10.0%明显升高(Pc<0.05，RR>1)。肺癌组的HLA-A*31频率为3.30%，A*33频率为6.70%，B*27频率为3.30%，B*52频率为6.70%，DRB1*03频率为0%，DRB3*01频率为60.0%，DQB1*02频率为0%，DQB1*06频率为0%，较对照组的23.30%、26.70%、26.70%、26.70%、23.30%、86.70%、23.30%、26.70%降低明显，(RR<1，Pc<0.05)。结论：云南肺癌易感性可能与HLA-A*02的频率(90%)具有相关性；而HLA-A*31、HLA-A*33、HLA-B*52、HLA-B*27、HLA-DRB1-*03、HLA-DRB3*01、HLA-DQB1*02及HLA-DQB1*06在肺癌患者中的频率较低，在云南肺癌发病中可能具有遗传拮抗作用。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate and observe the human leukocyte antigens HLA-A, B, DRB1, DQB1 alleles' frequency in Yun- nan human lung cancer, and explore the relationship between the Yunnan human lung cancer mobility and the human leukocyte antigens HLA alleles. Methods: Polymerase chain reaction-sequence specific primers(PCR-SSP) method was used to analyze the HLA-A, HLA-B, HLA-DRB1, HLA-DQB1 alleles from 30 Yunnan lung cancer patients, compared with control group. Additionally, relative risk(RR) was calculated and analyzed, subsequently. Results: The HLA-A*02 allele's frequency was up to 90.0%, particularly for A*0201, and B*46 allele's frequency was 40.0%, DRB1*15 was 40% in the lung cancer group. On the contrary, HLA-A*02 in control group was 43.30%. Meanwhile, B*46 was 0%, DRB1*15 was 10% in control group. The data obtained above were indicated that the frequencies in lung cancer group was significantly higher compared with those in the control group, RR<1, pc<0.05. Contrarily, in the lung cancer group, the frequency of HLA-A*31 was 3.30%, A*33 was 6.70%, B*27 was 3.30% , B*52 was 90.0%, DRB1*03 was 0%, DRB3*01 was 60.0%, DQB1*02 was 0%, DQB1*06 was 0%. However, the frequency of A*31 was 23.30%, A*33 was 26.70% in control group. Meanwhile, B*27 in control group was 26.60%, B*52 was 26.70%. DRB1*03 showed its frequency as 23.30%, and DRB3*01 was indicated as 86.70% in control group. DQB1*02 was detected as 23.30%, DQB1*06 was 26.70% in control group. The data indicated above showed its significantly lower tendency compared with control group, RR<1, pc<0.05. Conclusion: The HLA-A*02 allele, up to 90.0%, was showing its higher frequency in Yunnan lung cancer group, indicating its genetically predisposed possibility. Contrarily, HLA-A*31，HLA-A*33, HLA-B*27, HLA-B*52, as well as HLA-DRB1*03, HLA-DRB3*01, HLA-DQB1*02 and HLA-DQB1*06, which were lower in cancer group, might play its potential protective roles in lung cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
